We recommend using a newer internet browser, such as Google Chrome or Microsoft Edge, to optimize your browsing experience.

Skip to main content

Safety of New Formulation of Glatiramer Acetate (Song)

- Relapsing Remitting Multiple Sclerosis
- Completed

Study Title: Safety of New Formulation of Glatiramer Acetate

Teva Identifier: PM033

ClinicalTrials.gov Identifier: NCT00947752

Study Status: Completed

Trial Condition(s): Relapsing Remitting Multiple Sclerosis

Interventions: Drug: Glatiramer Acetate | Drug: Experimental Glatiramer Acetate

Study Description: Please refer to ClinicalTrials.gov for a description of the trial

Click for participation criteria and map of study locations

neurology icon for clinical trials

Key Participation Requirements

Gender: Female, Male

Age Range: 18 Years and older

Trial Duration: 07/01/2009 - 11/01/2009

Phase: Phase 3

Study Type

Interventional